HOB Biotech Group Corp Ltd - Asset Resilience Ratio
HOB Biotech Group Corp Ltd (688656) has an Asset Resilience Ratio of 2.62% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688656 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2022)
This chart shows how HOB Biotech Group Corp Ltd's Asset Resilience Ratio has changed over time. See HOB Biotech Group Corp Ltd (688656) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down HOB Biotech Group Corp Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HOB Biotech Group Corp Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥25.01 Million | 2.62% |
| Total Liquid Assets | CN¥25.01 Million | 2.62% |
Asset Resilience Insights
- Limited Liquidity: HOB Biotech Group Corp Ltd maintains only 2.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
HOB Biotech Group Corp Ltd Industry Peers by Asset Resilience Ratio
Compare HOB Biotech Group Corp Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351 |
Medical Devices | 49.23% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
Shenzhen Lifotronic Technology Co
SHG:688389 |
Medical Devices | 2.53% |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186 |
Medical Devices | 0.84% |
|
Eurobio Scientific SA
PA:ALERS |
Medical Devices | 10.52% |
Annual Asset Resilience Ratio for HOB Biotech Group Corp Ltd (2021–2022)
The table below shows the annual Asset Resilience Ratio data for HOB Biotech Group Corp Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 14.32% | CN¥135.23 Million ≈ $19.79 Million |
CN¥944.56 Million ≈ $138.22 Million |
+13.74pp |
| 2021-12-31 | 0.58% | CN¥5.01 Million ≈ $733.28K |
CN¥863.92 Million ≈ $126.42 Million |
-- |
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as an in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immune assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. HOB Biotech Group Corp.,Ltd was founded in 2009 and is ba… Read more